Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · October 17, 2022

Sapanisertib With or Without TAK-117 vs Everolimus in Patients With Advanced in Patients With Advanced RCC After VEGF-Targeted Therapy

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
Oncologist 2022 Sep 23;[EPub Ahead of Print], T Choueiri, C Porta, C Suárez, J Hainsworth, E Voog, I Duran, J Reeves, P Czaykowski, D Castellano, J Chen, F Sedarati, T Powles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading